IBDs including irritable bowel syndrome (ibs) or ulcerative colitis (uc) are a set of diseases developing into an epidemic. The unusual and recent rise in these kind of diseases most notably on developed countries point to a recent and area specific etiology, not a better healthcare and diagnosis.
Recent researchs are pointing to a healthier immune system and intestinal flora in undeveloped countries' population and an imbalance in our gut flora caused by excessive use of antibiotics.
For more information about health and wellbeing visit our site at:
http://findgoodhealth.org/
Microbiota, leaky gut syndrome and gut-related diseasesMaurizio Salamone
Lecture on "Microbiota, Leaky gut Syndrome and gut-related disease" at the 7° International workshop on Immunonutrition "Eating for preventing" Carovigno (BA) May 1st-3th 2014
Microbiota, leaky gut syndrome and gut-related diseasesMaurizio Salamone
Lecture on "Microbiota, Leaky gut Syndrome and gut-related disease" at the 7° International workshop on Immunonutrition "Eating for preventing" Carovigno (BA) May 1st-3th 2014
Mapping the Human Gut Microbiome in Health and Disease Using Sequencing, Supe...Larry Smarr
Invited Talk Delivered by Mehrdad Yazdani, Calit2 Ayasdi Sponsored Lunch & Learn American Society of Human Genetics (ASHG) San Diego Convention Center October 19, 2014
Ellen Kamhi, PhD RN, The Natural Nurse, Leaky Gut is also called Compromised Intestinal Permeability, due to loss of integrity of the tight junctions between cells in the intestinal mucosa, and is well documented in the scientific literature. See my document Role of Intestinal Permeability in the Inflammatory Process. This condition should be addressed by all health care providers.
Human nutrition, gut microbiome and immune system S'eclairer
Dr Zahida Chaudnary talks with the students about nutrition, gut microbiomes, and nutrition as we look at diseases and how your body reacts to what you eat.
Check out the slideshow by itself here.
Want an audio version? Subscribe to our Podcast on iTunes!
Want to join us for the live discussion? Check out our Social Media in the noon hour every Monday as we sit down on Google Hangout OnAir! Follow us on Twitter, Facebook, or Google+ to get updated with the link when we start!
Food allergy has been long recognized and well documented. Other adverse reactions to foods first referred to as “toxic idiopathies” by John Freeman, co inventor of immunotherapy, at the early part of the 1900s can be mediated by and have their impact on the nervous and endocrine systems. It can also be mediated by pharmacologic mechanisms and can also affect any part of the body. There’s a great clinical need to accurately identify triggers of adverse reactivity as they have now been linked with even the most serious of modern maladies and diseases. In fact, inflammation is the hallmark of metabolic syndrome. Given the multitude of pathogenic mechanisms underlying adverse reactions to foods and other environmental exposures it is necessary that a utilizable and cost effective technology be understood so that its application be utilized under the appropriate circumstances.
KEY LEARNING POINTS
• The natural ability of certain foods to initiate an inflammatory response and induce metabolic disruptions and counterbalancing mechanisms to prevent that
• How foods can trigger “danger signals” for the immune system
Pharmacologic vs. immunologic reactions to foods
• Is there a common final pathway of all these mechanisms that can reliably indicate triggers of clinical pathology?
• Cellular testing vs. serologic testing: The advantages of cellular testing
VHIR Seminar led by Joel Doré. Research Director. Institut National de la Recherche Agronomique (INRA). Jouy-en-Josas, France.
Abstract: The human intestinal tract harbours a complex microbial ecosystem which plays a key role in nutrition and health. Interactions between food constituents, microbes and the host organism derive from a long co-evolution that resulted in a mutualistic association.
Current investigations into the human faecal metagenome are delivering an extensive gene repertoire representative of functional potentials of the human intestinal microbiota. The most redundant genomic traits of the human intestinal microbiota are identified and thereby its functional balance. These observation point towards the existence of enterotypes, i.e. microbiota sharing specific traits but yet independent of geographic origin, age, sex etc.. It also shows a unique segregation of the human population into individuals with low versus high gene-counts. In the end, it not only gives an unprecedented view of the intestinal microbiota, but it also significantly expands our ability to look for specificities of the microbiota associated with human diseases and to ultimately validate microbial signatures of prognostic and diagnostic value in immune mediated diseases.
Metagenomics of the human intestinal tract was applied to specifically compare obese versus lean individuals as well as to explore the dynamic changes associated with a severe calory-restricted diet. Microbiota structure differs with body-mass index and a limited set of marker species may be used as diagnostic model with a >85% predictive value. Among obese subjects; the overall phenotypic characteristics are worse in individuals with low gene counts microbiota, including a worse evolution of morphometric parameters over a period of 10 years, a low grade inflammatory context also associated with insulin-resistance, and the worst response to dietary constraints in terms of weight loss or improvement of biological and inflammatory characteristics. Low gene count microbiota is also associated with less favourable conditions in inflammatory bowel disease, such as higher relapse rate in ulcerative colitis patients.
Finally, microbiota transplantation has seen a regain of interest with applications expanding from Clostridium difficile infections to immune mediated and metabolic diseases.
The human intestinal microbiota should hence be regarded as a true organ, amenable to rationally designed modulation for human health.
Evolution in the news (BIOL415) Spring 2014Kevin B Hugins
Mini presentation on current news stories for BIOL 415
This news article was about a journal article published in Nature Communications on April 15, 2014. The article is the result of research that was led by scientists from the Max Planck Institute for Evolutionary Anthropology. The purpose of the research was to study the co-evolution of humans and gut microbiota and examine adaptation that resulted in groups that had different diets. The primary group of interest was a hunter-gatherer group located in Tanzania known as Hadza. This is one of the few remaining true foraging populations in the world. The Hadza diet consists of baobab, game meat, honey, berries and tubers. Hadza do not consume any agricultural crops or livestock.
The Microbiome: Sorting the Hype from the Hope DrBonnie360
Content and Visual Design by Tiffany Simms
Cambridge Healthtech Institute's 23rd International Molecular-Med Tri-Con presents a short course on the Microbiome.
DrBonnie360 brings together two rising stars of the Sonnenburg Lab and the Knight Lab, and four microbiome companies, Second Genome, Osel Inc, AOBiome, and WholeBiome, to discuss the importance of the microbiome and how we can harness its power.
The course took place Sunday, March 6, 2016 in San Francisco.
Renée Wilson, Registered Dietitian and PhD Candidate at University of Otago, New Zealand. Presented at the 1st International Symposium on Kiwifruit and Health: http://www.kiwifruitsymposium.org/presentations/diet-microbiota-and-metabolic-health/
This cross-sectional pilot study aims to determine whether or not there are any differences between the gut microbiota of people with normal glucose tolerance, pre-diabetes and type 2 diabetes.
inflammatory bowel disease is a diagnosis of exclusion and it has two form known as crohn's disease which can affect all GI tract from ''gum to bum'' with skip lesion and the formation of cobblestones. ulcerative colitis affect only the colon and also causes proctitis and toxic megacolon. both of the disease has extraGI symptoms like sclerosing cholangitis, uveitis, ankylosing spondylitis,conjunctivitis, liver cirrhosis, pyoderma gangrenosum, arthropathy and althralgia, etc .
Mapping the Human Gut Microbiome in Health and Disease Using Sequencing, Supe...Larry Smarr
Invited Talk Delivered by Mehrdad Yazdani, Calit2 Ayasdi Sponsored Lunch & Learn American Society of Human Genetics (ASHG) San Diego Convention Center October 19, 2014
Ellen Kamhi, PhD RN, The Natural Nurse, Leaky Gut is also called Compromised Intestinal Permeability, due to loss of integrity of the tight junctions between cells in the intestinal mucosa, and is well documented in the scientific literature. See my document Role of Intestinal Permeability in the Inflammatory Process. This condition should be addressed by all health care providers.
Human nutrition, gut microbiome and immune system S'eclairer
Dr Zahida Chaudnary talks with the students about nutrition, gut microbiomes, and nutrition as we look at diseases and how your body reacts to what you eat.
Check out the slideshow by itself here.
Want an audio version? Subscribe to our Podcast on iTunes!
Want to join us for the live discussion? Check out our Social Media in the noon hour every Monday as we sit down on Google Hangout OnAir! Follow us on Twitter, Facebook, or Google+ to get updated with the link when we start!
Food allergy has been long recognized and well documented. Other adverse reactions to foods first referred to as “toxic idiopathies” by John Freeman, co inventor of immunotherapy, at the early part of the 1900s can be mediated by and have their impact on the nervous and endocrine systems. It can also be mediated by pharmacologic mechanisms and can also affect any part of the body. There’s a great clinical need to accurately identify triggers of adverse reactivity as they have now been linked with even the most serious of modern maladies and diseases. In fact, inflammation is the hallmark of metabolic syndrome. Given the multitude of pathogenic mechanisms underlying adverse reactions to foods and other environmental exposures it is necessary that a utilizable and cost effective technology be understood so that its application be utilized under the appropriate circumstances.
KEY LEARNING POINTS
• The natural ability of certain foods to initiate an inflammatory response and induce metabolic disruptions and counterbalancing mechanisms to prevent that
• How foods can trigger “danger signals” for the immune system
Pharmacologic vs. immunologic reactions to foods
• Is there a common final pathway of all these mechanisms that can reliably indicate triggers of clinical pathology?
• Cellular testing vs. serologic testing: The advantages of cellular testing
VHIR Seminar led by Joel Doré. Research Director. Institut National de la Recherche Agronomique (INRA). Jouy-en-Josas, France.
Abstract: The human intestinal tract harbours a complex microbial ecosystem which plays a key role in nutrition and health. Interactions between food constituents, microbes and the host organism derive from a long co-evolution that resulted in a mutualistic association.
Current investigations into the human faecal metagenome are delivering an extensive gene repertoire representative of functional potentials of the human intestinal microbiota. The most redundant genomic traits of the human intestinal microbiota are identified and thereby its functional balance. These observation point towards the existence of enterotypes, i.e. microbiota sharing specific traits but yet independent of geographic origin, age, sex etc.. It also shows a unique segregation of the human population into individuals with low versus high gene-counts. In the end, it not only gives an unprecedented view of the intestinal microbiota, but it also significantly expands our ability to look for specificities of the microbiota associated with human diseases and to ultimately validate microbial signatures of prognostic and diagnostic value in immune mediated diseases.
Metagenomics of the human intestinal tract was applied to specifically compare obese versus lean individuals as well as to explore the dynamic changes associated with a severe calory-restricted diet. Microbiota structure differs with body-mass index and a limited set of marker species may be used as diagnostic model with a >85% predictive value. Among obese subjects; the overall phenotypic characteristics are worse in individuals with low gene counts microbiota, including a worse evolution of morphometric parameters over a period of 10 years, a low grade inflammatory context also associated with insulin-resistance, and the worst response to dietary constraints in terms of weight loss or improvement of biological and inflammatory characteristics. Low gene count microbiota is also associated with less favourable conditions in inflammatory bowel disease, such as higher relapse rate in ulcerative colitis patients.
Finally, microbiota transplantation has seen a regain of interest with applications expanding from Clostridium difficile infections to immune mediated and metabolic diseases.
The human intestinal microbiota should hence be regarded as a true organ, amenable to rationally designed modulation for human health.
Evolution in the news (BIOL415) Spring 2014Kevin B Hugins
Mini presentation on current news stories for BIOL 415
This news article was about a journal article published in Nature Communications on April 15, 2014. The article is the result of research that was led by scientists from the Max Planck Institute for Evolutionary Anthropology. The purpose of the research was to study the co-evolution of humans and gut microbiota and examine adaptation that resulted in groups that had different diets. The primary group of interest was a hunter-gatherer group located in Tanzania known as Hadza. This is one of the few remaining true foraging populations in the world. The Hadza diet consists of baobab, game meat, honey, berries and tubers. Hadza do not consume any agricultural crops or livestock.
The Microbiome: Sorting the Hype from the Hope DrBonnie360
Content and Visual Design by Tiffany Simms
Cambridge Healthtech Institute's 23rd International Molecular-Med Tri-Con presents a short course on the Microbiome.
DrBonnie360 brings together two rising stars of the Sonnenburg Lab and the Knight Lab, and four microbiome companies, Second Genome, Osel Inc, AOBiome, and WholeBiome, to discuss the importance of the microbiome and how we can harness its power.
The course took place Sunday, March 6, 2016 in San Francisco.
Renée Wilson, Registered Dietitian and PhD Candidate at University of Otago, New Zealand. Presented at the 1st International Symposium on Kiwifruit and Health: http://www.kiwifruitsymposium.org/presentations/diet-microbiota-and-metabolic-health/
This cross-sectional pilot study aims to determine whether or not there are any differences between the gut microbiota of people with normal glucose tolerance, pre-diabetes and type 2 diabetes.
inflammatory bowel disease is a diagnosis of exclusion and it has two form known as crohn's disease which can affect all GI tract from ''gum to bum'' with skip lesion and the formation of cobblestones. ulcerative colitis affect only the colon and also causes proctitis and toxic megacolon. both of the disease has extraGI symptoms like sclerosing cholangitis, uveitis, ankylosing spondylitis,conjunctivitis, liver cirrhosis, pyoderma gangrenosum, arthropathy and althralgia, etc .
Detecting Early Liver Fibrosis - A Nutshell for Primary CareJarrod Lee
This presentation summarizes the latest technologies for detecting early liver fibrosis and their role in healthcare today. It is aimed at primary care doctors, to help them better utilize these new developments for their patients.
Understant what is obesity and Bariatric Surgery, what are the risk factors and how to overcome on the it. For more information visit at http://gisurgery.info
On the horizon: Critical Care and the Microbiome - Hallie PrescottIntensive Care Society
This is Hallie Prescott's presentation from the opening plenary session at the Intensive Care Society State of the Art Meeting 2018
Dr. Hallie Prescott is an Assistant Professor in Pulmonary & Critical Care Medicine at the University of Michigan and staff physician at the Ann Arbor Veterans Affairs Hospital. She leads grants on post sepsis morbidity and hospital performance measurement from the US National Institutes of Health and the US Department of Veteran’s Affairs. She is an expert in long-term outcomes and recovery after sepsis, with a focus on preventable hospital readmissions. She is co-chair of the Surviving Sepsis Campaign guidelines, inaugural Lowry-Fink fellow of the International Sepsis Forum (2017-2019), a former ANZICS Intensive Care Global Rising Star fellow (2015), and winner of the Early Career Achievement award from the American Thoracic Society’s Critical Care Assembly (2018).
LATHERSVETERINARY MEDICINE IN PUBLIC HEALTHCOMMENTARY COMMENTA.docxcroysierkathey
LATHERSVETERINARY MEDICINE IN PUBLIC HEALTHCOMMENTARY COMMENTARY
Role of Veterinary Medicine in Public Health:
Antibiotic Use in Food Animals and Humans
and the Effect on Evolution of
Antibacterial Resistance
Claire M. Lathers, PhD, FCP
VETERINARY PUBLIC HEALTH: A FRONTIER IN
THE FIGHT AGAINST HUMAN DISEASE
Veterinary public health is another frontier in the fight
against human disease.1 The veterinary public health
scope includes the control and eradication of zoonoses,
diseases that are naturally transmitted between verte-
brate animals and man. These diseases pose a continu-
ous hazard to the health and welfare of the public.
There are more than 100 diseases categorized as
zoonoses, including salmonellosis. For example, ap-
proximately 20% of U.S. broiler chickens are contami-
nated with Salmonella, while more that 80% are con-
taminated with Campylobacter.2 The veterinary public
health scope, in addition to the control and eradication
of zoonoses, also includes the development and super-
vision of food hygiene practices, laboratory and re-
search activities, and education of the public.
ANTIBIOTIC USE IN FOOD ANIMALS AND
HUMANS AND THE EFFECT ON EVOLUTION
OF ANTIBACTERIAL RESISTANCE
Antibiotic Use in Food Animals:
Therapeutic and Subtherapeutic
It is important to understand how antibiotics are used
in humans and in food animals and how these uses af-
J Clin Pharmacol 2001;41:595-599 595
From the U.S. Food and Drug Administration (FDA), Center for Veterinary
Medicine, Rockville, Maryland. This commentary represents the opinion of
the author and does not reflect policy of the FDA or the U.S. government.
Presented at the American College of Clinical Pharmacology Teaching Fo-
rum, chaired by David M. Benjamin, “Educational Issues in Clinical Phar-
macology: Updating the Curriculum for the New Millennium: Who Are Our
Audiences and What Are Their Specialized Needs? One Specialized
Need: Understanding the Role of Veterinary Medicine in Public Health,”
September 19, 2000. Address for reprints: Claire M. Lathers, PhD, FCP,
Director, Office of New Animal Drug Evaluation, Center for Veterinary
Medicine, Room 390, HFV-100, 7500 Standish Place, Rockville, MD
Veterinary public health is another frontier in the fight
against human disease. The veterinary public health scope
includes the control and eradication of zoonoses, diseases
that are naturally transmitted between vertebrate animals
and man. These diseases pose a continuous hazard to the
health and welfare of the public. More than 100 diseases are
categorized as zoonoses, including salmonellosis. It is im-
portant to understand how antibiotics are used in humans
and in food animals and how these uses affect the evolution
of antibacterial resistance. Appropriate use of antibiotics for
food animals will preserve the long-term efficacy of existing
antibiotics, support animal health and welfare, and limit the
risk of transfer of antibiotic resistance to humans. An under-
standing of the ep ...
Abdominal Tuberculosis Revisited–A single institutional experience of 72 case...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Similar to Irritable Bowel Syndrome (IBS) and Fecal Microbiota Transplant. A new hope for Inflammatory Bowel Diseases (20)
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
2. IBD are a set of diseases developing
into an epidemic
The unusual and recent rise in these kind of diseases most
notably on developed countries point to a recent and area
specific etiology, not a better healthcare and diagnosis.
Recent research are pointing to a healthier immune system and
intestinal flora in undeveloped countries and population
• First Look at the Microbes of Modern Hunter-Gatherers
Pharma companies are incresing their budget to investigate new
drugs to treat Chron’s Disease and Ulcerative Colitis.
Sidney, Scotland and Calgary public health services are
investigating the rise of these diseases reaching epidemic
proportions, specially on children population
• IBD on the Rise Worldwide, more on developed countries
• Kid’s Chron epidemic in Scotland
• IBD on the rise in Ontario specially on children
3. Research hints flora imbalance as
the most probable cause
Researchers discover the cause of Irritable Bowel Syndrome.
Professor Michael Schemann’s research team at the TUM Department for Human
Biology demonstrated that micro-inflammations of the mucosa causes sensitization
of the enteric nervous system, which in turn causes irritable bowel syndrome. The
researchers used ultrafast optical measuring methods to demonstrate that
mediators from mast cells and enterochromaffin cells directly activate the nerve
cells in the bowel. The hypersensitivity of the enteric nervous system upsets
communication between the gut’s mucosa and its nervous system. Project leader
Prof. Schemann explained: “The irritated mucosa releases increased amounts of
neuroactive substances such as serotonin, histamine and protease. This cocktail
produced by the body could be the real cause of the unpleasant IBS complaints.”
The scientists are the first to identify IBS’s cause; up to now, many doctors have
dismissed their IBS patients as merely being hypochondriacs. Irritable bowel
syndrome makes life miserable for those affected — an estimated ten percent or
more of the population. And what irritates many of them even more is that they
often are labeled as hypochondriacs, since physical causes for irritable bowel
syndrome have never been identified until now.
4. Sources
• Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H,
Michel K, Schemann M: “Activation of human enteric neurons by supernatants of colonic biopsy
specimens from patients with irritable bowel syndrome”. Gastroenterology. 2009; 137: 1425-1434.
• Abstract
• Schneider J, Jehle EC, Starlinger MJ, Neunlist M, Michel K, Hoppe S, Schemann M: “Neurotransmitter
coding of enteric neurons in the submucous plexus is changed in non-inflamed rectum of patients with
Crohn's disease”. Neurogastroenterol Motil. 2001; 13: 255-264.
• Abstract
Academic Career and Research Areas
Prof. Schemann’s (b. 1956) research focuses on the neural regulation of gastrointestinal
functions. With the aid of ultrafast imaging, he investigates the neurophysiology and
neuropharmacology of the human enteric nervous system. As well as exploring basic
neurobiological issues, he also examines the role of the enteric nervous system in the
pathogenesis of functional and inflammatory diseases of the gut. Another aspect of his work
involves identifying new targets to treat these diseases. After studying agricultural biology,
Prof. Schemann did his doctorate (1985) and lecturer qualification (1990) at the University of
Hohenheim. During that time, a German Research Foundation grant enabled him to work at
Ohio State University, USA. He received a Heisenberg grant to work at the Max Planck
Institute for Physiological and Clinical Research in Bad Nauheim. In 1994, he became professor
of vegetative physiology at the University of Veterinary Medicine in Hannover. Since 2002, he
has been full professor of human biology at TUM. Prof. Schemann is a member of the editorial
board of Gastroenterology and Gut.
5. Further research blames extensiveuse
of antibiotics as cause of imbalance
Gut Biota Never Recover from Antibiotic Use: Loss
Extends to Future Generations
Evidence shows the mass antibiotics experiment is devastating our children’s
health. It may be the reason so many struggle for breath and can’t assimilate food
properly.
Emerging research shows that the harmful effects of antibiotics go much further than the development of
drug resistant diseases. The beneficial bacteria lost to antibiotics, along with disease-inducing bacteria, do
not recover fully. Worse, flora lost by a mother is also lost to her babies. The missing beneficial gut bacteria
are likely a major factor behind much of the chronic disease experienced today. The continuous use of
antibiotics is resulting in each generation experiencing worse health than their parents.
Martin Blaser is chair of the Department of Medicine, New York University Langone Medical Center. Is the
author of a report in the prestigious journal Nature and he writes:
Antibiotics kill the bacteria we do want, as well as those we don’t. These long-term changes to the
beneficial bacteria within people’s bodies may even increase our susceptibility to infections and disease.
Overuse of antibiotics could be fuelling the dramatic increase in conditions such as obesity, type 1 diabetes,
inflammatory bowel disease, allergies and asthma, which have more than doubled in many populations.
Aside from the development of superbugs, we’re now seeing clear documentation that the overall long
term effects of antibiotics are devastatingly harmful to our health. Speaking to ABC News, Blaser said:
Antibiotics are miraculous. They’ve changed health and medicine over the last 70 years. But when doctors
prescribe antibiotics, it is based on the belief that there are no long-term effects. We’ve seen evidence that
suggests antibiotics may permanently change the beneficial bacteria that we’re carrying.
6. Sources
• Enterotypes of the human gut microbiome
• The changing hypothesis of the gut
• Antibiotic overuse: Stop the killing of beneficial bacteria
7. Gastroenterologists worldwide
make a breakthrough
Fecal transplants successful in treating intestinal ailment
An infusion of feces from a healthy person is much more effective than an antibiotic in treating C.
difficile, a recurrent intestinal infection, researchers find.
A new study has found that an infusion of feces from a healthy person into an ailing patient's gut was
significantly more effective than a traditional antibiotic treatment — raising hopes that the
unconventional approach could one day help combat obesity, food allergies and a host of other
maladies.
The study, published online Wednesday by the New England Journal of Medicine, a reference
magazine for the medical community worldwide, demonstrated that the fecal transplant cleared up a
recurrent bacterial infection far more reliably than the routinely prescribed medication. In fact, the
transplant was so successful that the research trial was ended early so that patients in the control
groups could be given the remedy as well.
As a treatment for recurrent Clostridium difficile infection — an ailment that affects nearly 1% of
patients hospitalized in the U.S. and plays a role in an estimated 100,000 deaths a year — the
transplant had a 94% cure rate, three times greater than for those who took only the antibiotic
vancomycin.
"It's a strange concept to use stool, which has always been looked on as something dirty," said Dr.
Lawrence Brandt, a gastroenterologist at the Albert Einstein College of Medicine in New York who has
conducted transplants for 14 years but wasn't involved in the study. "We're entering a very exciting
new chapter in medicine."[…]
Source
The New England Journal of Medicine
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
8. Fecalmicrobiotatransplantationfor
severeenterocolonic fistulizingCrohn's
disease.
• Authors Zhang FM, et al. Show all Journal
• World J Gastroenterol. 2013 Nov 7;19(41):7213-6. doi: 10.3748/wjg.v19.i41.7213.
Affiliation
Fa-Ming Zhang, Hong-Gang Wang, Min Wang, Bo-Ta Cui, Zhi-Ning Fan, Guo-Zhong Ji, Digestive
Endoscopy and Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing
Medical University, Nanjing 210011, Jiangsu Province, China.
Abstract
The concept of fecal microbiota transplantation (FMT) has been used in traditional Chinese
medicine at least since the 4(th) century. Evidence from recent human studies strongly supports
the link between intestinal bacteria and inflammatory bowel disease. We proposed that
standardized FMT might be a promising rescue therapy for refractory inflammatory bowel
disease. However, there were no reports of FMT used in patients with severe Crohn's disease
(CD). Here, we report the successful treatment of standardized FMT as a rescue therapy for a
case of refractory CD complicated with fistula, residual Barium sulfate and formation of
intraperitoneal large inflammatory mass. As far as we know, this is the first case of severe CD
treated using FMT through mid-gut.
Source
http://www.ncbi.nlm.nih.gov/m/pubmed/24222969/
9. Rebiotix Clinical Program
Developing solutions for difficult-to-treat gastrointestinal diseases
Rebiotix is pursuing a focused clinical research program to develop new
solutions to challenging gastrointestinal diseases.
The company’s first target is recurrent Clostridium difficile (C diff), a
healthcare-acquired infection that has been termed an urgent public
health threat by the US Centers for Disease Control.
About RBX2660
Lead product, RBX2660 (microbiota suspension) is currently undergoing
Phase 2 evaluation in the PUNCH™ CD study.
Rebiotix is currently working with the US Food and Drug Administration
(FDA) on the design for a Phase 3 study of the product.
RBX2660 is a second generation version of fecal transplant therapy
featuring a number of refinements designed to improve on a non-
antibiotic technique that has been used to treat recurrent C diff
successfully.
The company is also actively exploring additional
products for other gastrointestinal diseases.
10. The Centre for Digestive Diseases
for Research And Treatment
The Centre for Digestive Diseases (CDD), under the leadership of
founder and Medical Director, Professor Thomas Borody, has
distinguished itself as a unique medical institution offering novel
approaches in researching, diagnosing and treating gastrointestinal (GI)
conditions.
CDD offers a range of services in the day-procedure unit. Patients
undergo a range of procedures in its well-equipped facilities, supported
by an ISO 9002 accredited organisation consisting of 38 staff. CDD offers
patients a high standard of professional care and service.
CDD also houses a Department of Research and Innovation responsible
for conducting clinical trials approved by an independent Human
Research Ethics Committee (HREC).
Located in Sydney Australia, CDD is internationally regarded as a unique
medical institution, collaborating with pharmaceutical companies,
universities and medical societies in striving to provide excellence in
gastroenterology.
11. Our recent publications and
abstracts
• Anti-MAP therapy in the treatment of active Crohn's disease.
T.J. Borody, R. Clancy, A. Wettstein, K.J. Herdman, M. Torres, S. Tye, G.
Pang, E. Campbell, S. Leis.
Journal of Gastroenterology and Hepatology 2005; 20(Suppl): A2.
• Bacteriotherapy using fecal flora: toying with human motions.
TJ Borody, EF Warren, SM Leis, R Surace, O Ashman, S Siarakas.
J Clin Gastroenteroly 2004; 38(6): 475-83.
• Irritable bowel syndrome and Dientamoeba fragilis.
TJ Borody, C Robertson, A Wettstein, E Warren, R Surace.
IBIS News and Views. Winter 2002; 4-5.
• For a complete list refer to
http://cdd.com.au/pages/publications/publications_abstracts.html
12. OpenBiome First to Market in the
US with Fecal Microbiota
About OpenBiome
OpenBiome is a nonprofit organization dedicated to expanding access
to fecal microbiota transplantation (FMT) therapies. Founded by a small
team of microbiologists, public health advocates, and concerned
citizens, OpenBiome aims to significantly reduce the practical barriers
for clinicians providing FMTs, while connecting scientists across studies
and disciplines.
Why did we launch OpenBiome?
Motivated by scientific curiosity and frustration at the struggle of a
friend suffering from recurrent C. difficile, we founded the OpenBiome
project to give a broader pool of clinicians access to the carefully
screened samples necessary to perform FMT.
Despite the underlying simplicity and efficacy of FMT, it has become
difficult to practice at the scale required due to the challenges of
screening donors and processing stool material. OpenBiome is designed
to simplify the FMT process by freeing clinicians to focus on providing
care and conducting research rather than preparing stool and filing
paperwork.
13. Doctor’s clinical experience on
FMT
Dr. Thomas Borody from the Centre for Digestive
Diseases.
Fecal Bacteriotherapy (Human Probiotic Infusion) for Clostridium
difficile infection.
14. Dr. Lawrence Brandt
Lawrence Brandt, MD, professor of medicine and surgery at the Albert
Einstein College of Medicine in New York City, discusses a study on the
outcomes of fecal microbiota transplants on almost 100 patients across
the country with refractory Clostridium difficile colitis. He explains that
91 percent of the patients experienced prompt relief. Including those
who underwent a second transplant or a post-transplant course of
medication, 98.3 percent of the patients experienced relief.
15. Dr. Carl V. Crawford
Carl V. Crawford, M.D., a gastroenterologist at the
Center for Advanced Digestive Care at NewYork-
Presbyterian, explains Fecal Microbiota
Transplantation as a treatment for Ulcerative
Colitis.
16. The Power of Poop
• Leading website compiling success stories of patients that
have been treated with FMT
• http://thepowerofpoop.com/